Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_assertion type Assertion NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_head.
- NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_provenance.
- NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_assertion evidence source_evidence_literature NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_provenance.
- NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_assertion SIO_000772 22653055 NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_provenance.
- NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_assertion wasDerivedFrom befree-2016 NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_provenance.
- NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_assertion wasGeneratedBy ECO_0000203 NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_provenance.